EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Pooled screening for CAR function identifies novel IL-13Rα2-targeted CARs for treatment of glioblastoma

Khloe S Gordon, Caleb R Perez, Andrea Garmilla, Maxine S Y Lam, Joey J Y Aw, Anisha Datta, Douglas A Lauffenburger, Andrea Pavesi, Michael E Birnbaum

Journal for ImmunoTherapy of Cancer · 2025-02 · 13 (2) · e009574

DOI: 10.1136/jitc-2024-009574 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal for ImmunoTherapy of Cancer, online erschienen am 11.02.2025. Verfasst von Khloe S Gordon und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA. Hauptthemen laut MEDLINE: Glioblastoma, Interleukin-13 Receptor alpha2 Subunit, Receptors, Chimeric Antigen, Immunotherapy, Adoptive. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 87 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NCI NIH HHS, NIGMS NIH HHS, Koch Institute Frontier Research Program.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Chimeric antigen receptor (CAR) therapies have demonstrated potent efficacy in treating B-cell malignancies, but have yet to meaningfully translate to solid tumors. Nonetheless, they are of particular interest for the treatment of glioblastoma, which is an aggressive form of brain cancer with few effective therapeutic options, due to their ability to cross the highly selective blood-brain barrier.

Methods

Here, we use our pooled screening platform, CARPOOL, to expedite the discovery of CARs with antitumor functions necessary for solid tumor efficacy. We performed selections in primary human T cells expressing a library of 1.3×10 6 third generation CARs targeting IL-13Rα2, a cancer testis antigen commonly expressed in glioblastoma. Selections were performed for cytotoxicity, proliferation, memory formation, and persistence on repeated antigen challenge.

Results

Each enriched CAR robustly produced the phenotype for which it was selected, and one enriched CAR triggered potent cytotoxicity and long-term proliferation on in vitro tumor rechallenge. It also showed significantly improved persistence and comparable tumor control in a microphysiological human in vitro model and a xenograft model of human glioblastoma, but also demonstrated increased off-target recognition of IL-13Rα1.

Conclusion

Taken together, this work demonstrates the utility of extending CARPOOL to diseases beyond hematological malignancies and represents the largest exploration of signaling combinations in human primary cells to date.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GlioblastomaInterleukin-13 Receptor alpha2 SubunitReceptors, Chimeric AntigenImmunotherapy, AdoptiveBrain NeoplasmsHumansAnimalsMiceXenograft Model Antitumor AssaysCell Line, TumorCell Proliferation

Stichwörter der Autor:innen

Chimeric antigen receptor - CART cell

Substanzen

Interleukin-13 Receptor alpha2 SubunitReceptors, Chimeric AntigenIL13RA2 protein, human

Autor:innen und Institutionen

  • Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA.
  • Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA.
  • Singapore-MIT Alliance for Research and Technology Centre, Singapore.
  • Program in Immunology, Harvard Medical School, Boston, Massachusetts, USA.
  • Institute of Molecular and Cell Biology, Agency for Science Technology and Research (A*STAR), Singapore.
  • Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore.

Förderung

  • NCI NIH HHS
  • NIGMS NIH HHS
  • Koch Institute Frontier Research Program
  • Deshpande Center
  • Ludwig graduate fellowship
  • National Institute of General Medical Sciences
  • National Science Foundation Graduate Research Fellowship Program
  • National Cancer Institute

Zitieren

APA

Gordon, K. S., Perez, C. R., Garmilla, A., Lam, M. S. Y., Aw, J. J. Y., Datta, A., Lauffenburger, D. A., Pavesi, A., & Birnbaum, M. E. (2025). Pooled screening for CAR function identifies novel IL-13Rα2-targeted CARs for treatment of glioblastoma. Journal for ImmunoTherapy of Cancer, 13(2), e009574. https://doi.org/10.1136/jitc-2024-009574

Vancouver

Gordon KS, Perez CR, Garmilla A, Lam MSY, Aw JJY, Datta A, et al. Pooled screening for CAR function identifies novel IL-13Rα2-targeted CARs for treatment of glioblastoma. Journal for ImmunoTherapy of Cancer. 2025;13(2):e009574. doi:10.1136/jitc-2024-009574

BibTeX
@article{Gordon2025,
  author = {Gordon, Khloe S and Perez, Caleb R and Garmilla, Andrea and Lam, Maxine S Y and Aw, Joey J Y and Datta, Anisha and Lauffenburger, Douglas A and Pavesi, Andrea and Birnbaum, Michael E},
  title = {Pooled screening for CAR function identifies novel IL-13Rα2-targeted CARs for treatment of glioblastoma},
  journal = {Journal for ImmunoTherapy of Cancer},
  year = {2025},
  volume = {13},
  number = {2},
  pages = {e009574},
  doi = {10.1136/jitc-2024-009574}
}
Kostenlos starten →